Phase I and phase II reductive metabolism simulation ... - Springer Link
Recommend Documents
MZmine. ⢠Detected masses, built chromatograms, deconvoluted, deisotoped. ⢠Aligned features. R. ⢠Calculated fold-change (FC) between samples and controls.
Feb 22, 2012 - Expression values are shown for liver (A), small intestine (B), kidney. (C), and lung (D) ...... Falany, C.N.; Johnson, M.R.; Barnes, S. & Diasio, R.B. (1994). Glycine and taurine .... honor of Wendell W. Weber. Drug Metabolism ...
May 20, 2015 - People's Republic of China. 2. Cancer Immunology and Immunotherapy Center, The. Affiliated Hospital of Guiyang Medical College, 28 Guiyi.
Oct 11, 2010 - Background. KS is a disease of multifocal vascular proliferation that requires infection with the KS herpes virus (KSHV/. HHV-8). Activation of ...
Sep 24, 2017 - of the cytochrome P450 system may alter susceptibility to lung cancer. (2). It is hypothesized that genetic variations in these metabolism genes.
When combining the PARP1 inhibitor olaparib with cisplatin in a BRCA1-mutated breast cancer mouse model, the combination induced a larger response than ...
Synthesis, Analysis, and Enantioselective in vitro and in vivo. Kinetics ... After
decreasing numbers of MDMA users in recent years, most likely due to its ...
Liposome-Based Drug Delivery Systems, ... final particle size and distribution. ..... Chupin VV, Torchilin VP (2015) New developments in liposomal drug delivery.
Oct 3, 2009 - Abstract Chronic inflammation is one of the main features of cancer cachexia. Experimental and clinical studies showed that cyclooxygenase-2 ...
Basil F. El-Rayes1, Mark M. Zalupski2, Anthony F. Shields1, Ann Marie ... (COX-2) enzyme plays a major role in tumor progression and resistance to therapy.
Mar 12, 2013 - Edith A. Perez. Received: 21 ... e-mail: [email protected] ...... Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A,. Untch M ...
Page 1. Oxbow. B e n d. S id e w in d e r. D riv e. H o riz o n. B o u le v a rd. Hardy Way. Falcon Ridge Parkway. Canyo
Section 3 presents the data, and Section 4 displays the results of cointegration ... price driver for the EU ETS spot market in 2005 but not in 2006. ..... However, accounting for the 2006 structural change leads us to recover a .... hard coal), and
A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
Dec 12, 2008 - Received: 27 August 2008 / Accepted: 20 November 2008 / Published online: 12 ..... first day of treatment until death or was censored on the.
Sep 28, 2013 - of the combination of Sorafenib (S), and Oxaliplatin as second- ... The com- bination of Oxaliplatin-Sorafenib in advanced GC patients.
Oct 8, 2015 - therapy for sorafenibârefractory advanced hepatocellular carcinoma. Andrew Gabrielson1 · Anteneh A. Tesfaye1 · John L. Marshall1 ·. Michael ...
Competence Models. (14) ... Cultural. Competence. 4 item reduction rounds separately by 3 researchers ... Phase II: Psychometric Evaluation of the CCCHP-EU.
Phase II Implementation Action Plan ... Evaluation Plan ... for Diabetes Care
program is developing and evaluating innovative ways to ... Examples of
intervention ... as channels of communication, education, advocacy or support,
such as group ...
Aug 1, 2006 - ... P.O. Box 85800, San Diego, California 92186. The authors listed in the manuscript (S.R., X.H., H.-E.Z., H.W., S.K.D.) have nothing to declare.
Mar 17, 2011 - Department of Civil Engineering, Schulich School of Engineering, University of ... and Thomson 2003) have demonstrated that the cubic law is ...
Jul 6, 2012 - Summary Purpose Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest en- hanced antitumor ...
Phase I and phase II reductive metabolism simulation ... - Springer Link
Sep 19, 2014 - niclosamide and nilutamide are used in cancer therapy. At first, a flow-through electrochemical cell was directly con- nected to a high resolution ...
Anal Bioanal Chem (2014) 406:7253–7260 DOI 10.1007/s00216-014-8171-3
RESEARCH PAPER
Phase I and phase II reductive metabolism simulation of nitro aromatic xenobiotics with electrochemistry coupled with high resolution mass spectrometry Ugo Bussy & Yu-Wen Chung-Davidson & Ke Li & Weiming Li
Received: 6 August 2014 / Revised: 3 September 2014 / Accepted: 5 September 2014 / Published online: 19 September 2014 # Springer-Verlag Berlin Heidelberg 2014
Abstract Electrochemistry combined with (liquid chromatography) high resolution mass spectrometry was used to simulate the general reductive metabolism of three biologically important nitro aromatic molecules: 3-trifluoromethyl-4nitrophenol (TFM), niclosamide, and nilutamide. TFM is a pesticide used in the Laurential Great Lakes while niclosamide and nilutamide are used in cancer therapy. At first, a flow-through electrochemical cell was directly connected to a high resolution mass spectrometer to evaluate the ability of electrochemistry to produce the main reduction metabolites of nitro aromatic, nitroso, hydroxylamine, and amine functional groups. Electrochemical experiments were then carried out at a constant potential of −2.5 V before analysis of the reduction products by LC-HRMS, which confirmed the presence of the nitroso, hydroxylamine, and amine species as well as dimers. Dimer identification illustrates the reactivity of the nitroso species with amine and hydroxylamine species. To investigate xenobiotic metabolism, the reactivity of nitroso species to biomolecules was also examined. Binding of the nitroso metabolite to glutathione was demonstrated by the observation of adducts by LC-ESI+-HRMS and the characteristics of their MSMS fragmentation. In conclusion, electrochemistry produces the main reductive metabolites of nitro aromatics and supports the observation of nitroso reactivity through dimer or glutathione adduct formation.
Electronic supplementary material The online version of this article (doi:10.1007/s00216-014-8171-3) contains supplementary material, which is available to authorized users. U. Bussy : Y.
